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ABSTRACT  
In present study Orodispersible tablets (ORDT) of Loratadine were prepared and optimized. Solid dispersion of Loratadine- β cyclodextrin 
complex were prepared and used in preparation of Orodispersible tablets. Various super-disintegrating agent like Cross carmellose sodium, 
Cross povidone and Kyron T-314 were employed for faster disintegrating effect. The 24 factorial and Box-Behnken design were utilized to 
optimize the tablet formulation. The Orodispersible tablet of Loratadine was optimized by Box Behnken Design, where concentrations Kyron T-
314, CRP and Pearlitol SD200 were employed and its effect on Disintegration time (DT), Wetting time (WT) and % drug release at 20 min (Q20) 
was evaluated. Precompression parameters like angle of repose, bulk density, % compressibility, Hausner’s ratio was studies. The different 
batches of Orodispersable tablets were prepared and evaluated for disintegration time, friability, wetting time and drug release studies. 
Different batches prepared showed disintegration time in the range of 23 ± 2.52 to 59 ± 2.64, wetting time in between 27± 0.57 to 66.3 ± 3.4, 
drug release (Q 20) in between 86.1 ± 0.6 to 96.7 ± 0.4 in 20 min., friability less than 1 % and hardness 3.4 to 4.2 Kg/cm2. The optimized 
formula when compared with marketed product it showed faster disintegration time and rapid drug dissolution in phosphate buffer 6.8. The 
solid dispersion of Loratadine not only helped improve in solubility but may also help in taste masking.  
Keywords: Orodispersible tablets, Loratadine, β cyclodextrin Solid dispersion 
 
Article Info: Received 11 July 2019;     Review Completed 17 August 2019;     Accepted 21 August 2019;     Available online 30 Aug 2019 
Cite this article as: 
Kundawala A, Patel P, Chauhan K, Desai A , Kapadia D, Formulation and Optimization of Orodispersible Tablet of 
Loratadine Using Box Behnken Design, Journal of Drug Delivery and Therapeutics. 2019; 9(4-A):86-94    
http://dx.doi.org/10.22270/jddt.v9i4-A.3402                                                      
*Address for Correspondence:  
Dr. Aliasgar Kundawala, Associate Professor, Dept. Of Pharmaceutics and Pharmaceutical Technology, Indukaka Ipcowala College of Pharmacy, 




Tablet stands for most affordable and patient friendly 
dosage form because of its convenience in self 
administration, compactness and easy manufacturing. 
However, in certain conditions tablet offers little 
inconvenience such as in case of elderly patients, bad ridden 
patient or in certain medical conditions where faster action 
in desirable that leads to high incidence of non-compliance 
and ineffective therapy. Patient convenience and compliance 
oriented research has resulted in bringing out many safer 
and newer drug delivery systems. Rapidly disintegrating / 
dissolving tablet is one of such examples. Fast disintegrating 
tablets are gaining prominence as new drug delivery 
systems. These dosage forms dissolve or disintegrate in the 
oral cavity within a minute without the need of water or 
chewing. Orodispersible Tablets (ORDTs) are suitable for 
numerous indications ranging from migraines (for which 
rapid onset of action is important), in mental illness (where 
patient compliance is important for treating chronic 
indications such as depression and schizophrenia), in 
motion sickness, sudden episodes of coughing during the 
common cold, allergic condition and bronchitis. This 
attribute makes these dosage forms highly attractive 
product for the pediatric, geriatric and dysphasic patients1-2. 
Orodispersible tablets usually disintegrate or dissolve 
rapidly in saliva. Saliva in the mouth coused the tablet to 
disintegrate within few seconds and get dispersed or 
dissolved in saliva. In this way the drug is available and 
absorbed before reaching stomach. This makes the drug 
avoid first pass metabolism and give faster therapeutic 
effect. This makes orodispertablet achieve better 
bioavailability compared to conventional tablet dosage 
form3-4.  
The Orodispersible tablets are prepared either by use of 
superdisintegrants, effervescent approach or by sublimation 
technique. Various superdisintegrants such as sodium starch 
glycolate, crosspovidone, cross carmellose sodium, resins or 
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other natural polymers like husk are used in preparation of 
Orodispersible tablets. The superdisintegrating agent 
basically provides disintegration by swelling, wicking or 
capillary actions after absorption of water that couses 
busting of tablet or grabules5. 
Researchers have worked on ODT formulations for various 
categories of drugs, which are used for therapy in which 
rapid peak plasma concentration is required to achieve 
desired pharmacological response. These include 
neuroleptics, cardiovascular agents, antihistamines and 
analgesics. Orally disintegrating tablets are tailor made for 
these patients as they immediately release the active drug, 
when placed on the tongue, by rapid disintegration, followed 
by dissolution of the drug. European pharmacopoeia defines 
“Orodispersible tablets are uncoated tablets intended to be 
placed in the mouth where they disperse rapidly before 
being swallowed”. Orodispersible tablets disintegrate within 
3 minutes 6-7. To improve the dissolution and bioavailability 
of poorly soluble drugs, researchers have employed various 
techniques, such as micronization, solubilization, salt 
formation, complexation with polymers, and change in 
physical form, use of prodrug and drug derivatization, 
alteration in pH, addition of surfactants8.   
Loratadine is a second generation non sedative 
antihistamine drug that reduces the effects of natural 
chemical histamine in the body. Histamine can produce 
symptoms of sneezing, itching, watery eyes, and runny nose. 
It is also used in the treatment of allergic skin disorder, 
specially atopic dermatitis and urticaria, allergic rhinitis, 
acute coryza, ocular allergies at the dose of 10 mg once a day 
in adult and 5 mg (if ˂30 kg) or 10 mg (if ˂30 kg) in 2 – 12 
years children9-10. It’s like other H1-blockers, loratadine 
competes with free histamine for binding at H1-receptors in 
the GI tract, uterus, large blood vessels, and bronchial 
muscle.  
Loratadine is a poorly soluble drug and indicated in 
treatment of allergic rhinitis (AR) and chronic idiopathic 
urticaria (CIU). The poorly water-soluble drugs often show 
an erratic dissolution profile in gastrointestinal fluids, which 
consequently results in variable oral bioavailability. In 
present study investigation was carried out to prepare 
Orodispersible tablet of Loratadine using different 
superdisintegrants at different concentration level to 
enhance bioavailability and patient compliance. 
MATERIAL AND METHODS 
Loratadine (LRD) was kindly provided by Cadila 
Pharmaceuticals Ltd. India. β-Cyclodextrin (β-CD) was 
provided by Mercury Lab. Pvt. Ltd., Baroda, India. Pearlitol 
SD 200 was provided by Roquette pharma, France. Kyron T 
314 and Crosspovidone (CRP) was supplied by Corel Pharm 
Ltd. India. Crosscarmellose sodium (CS) and sodium starch 
glycolate (SSG) was purchased from Sunrise remedies Pvt. 
Ltd, India. Magnesium Stearate, aerosol, microcrystalline 
cellulose and aspartame was purchased from Chemdyes 
Corporation, Ahmedabad, India.  All other reagents used are 
of analytical grade.  
Formulation of orodispersible tablet of Loratadine –β 
cyclodextrin complex. 
The orodeispersabale tablet were prepared by direct 
compression method. The Loratadine- β cyclodextrin solid 
dispersion was used in preparation of orodispersible tablet. 
Loratadine is a poorly water soluble drug. The drug β-
cyclodextrin complex was prepared to enhance solubility as 
described in our previous work11. In brief, the complexation 
of Loratadine with β-cyclodextrin was formed by kneading 
method using 1:3 molar ratio respectively. This Loratadine- 
β cyclodextrin complex showed solubility of 1720 μg/ml. In 
tablet formulation, all the ingredients were passed through 
sieve No #100 before blending. The blend was prepared by 
mixing all the ingredients and lubricated with magnesium 
stearate and talc later. The resultant powder blend was then 
compressed into tablets using 8 mm flat punch in rotary 
tablet punching machine. Tablets were evaluated for weight 
variation, hardness, and friability and disintegration time.  
Application of 24 factorial design 
24 factorial design was introduced to screen formulation 
variables that may influence the attributes of orodispersible 
tablet. In present study four factors, amount of Kyron T-314 
(KT)(2-6%), CRP (5-10%) Pearlitol SD 200 (15-25%) and 
hardness (3-4 kg/cm2) were taken and tested for 16 runs.  
Other formulation and process parameters were kept 
constant. The disintegration time and wetting were taken as 
response variables. The Design Expert software 8.0.1.7 was 
used to generate and randomize the design matrix for 
statistical analysis. The experimental runs were 
experimented thrice. The disintegration time and wetting 
time were considered as dependent variables. The design 
matrix for 24 factorial design and various factors involved 
are shown in Table 1 and 2. 
Y = bo + bl X1 + b2 X2 + b3 X3 + b4 X4 + b12 X1 X2 + b13 X1 X3 + 
b14 X1 X4 + b23 X2 X3 + b24 X2 X4 + b34 X3 X4 + b123 X1 X2 X3 + 
b124 X1 X2 X4 + b134 X1 X3 X4 + b234 X2 X3 X4 + b1234 X1 X2 X3 X4 + 
e 
Where Y is the dependent variable, b0 is the arithmetic mean 
response of the 16 runs and bi is the estimated coefficient for 
the factor X1, X2, X3 and X4. The main effects (X1and X2) 
represent the average result of changing one factor at a time 
from its low to high value. The interaction terms (X1 X2 X3) 
show how the response changes when three factors are 
simultaneously changed. Layout of design is shown in the 
Table 2. 
Statistically validity of the model was established on the 
basis of ANOVA provision provided in the Design Expert 
software 8.0.1.7. Using 5% significance level, the model was 
considered significant, if the p value was less than 0.05 (p < 
0.05) 
Optimization of Loratadine ODT by Box Behnken design 
The optimization of orodispersible tablet formulations 
containing LCD complex were carried out using three level, 
three factor Box-Behenken design approach. It is a kind of 
response surface methodology.  Here, significant factors 
identified from of 24 factorial design were subjected further 
evaluation of at three levels. The design consists of 
replicated centre points and a set of points lying at the 
midpoints of each edge of the multidimensional cube that 
defines the interesting area. Amount of Kyron T-314 
(Superdisintegrant), CRP (Superdisintegrant) and  Pearlitol 
SD 200 (pore-forming agent) were selected as three 
independent variables X1, X2 and X3, respectively. Other 
formulation component and process parameters were fixed. 
Again design Expert 8.1.0.7 was employed to statistically 
evaluate and randamize design matrix. Disintegration times 
(R1), Wetting time (R2), Cumulative percentage of drug 
release at 20 min (R3) and Friability (R4) were taken as 
response variables. Layout of design is shown in the Table 3. 
Polynomial models including interaction and quadratic 
terms were generated for three response variables using 
multiple linear regression analysis (MLRA) approach. 
The general form of the MLRA model is represented as the 
following equation: 
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R = b0 + b1X1 + b2X2+ b3X3 + b4X1X2+ b5X1X3+ b6X2X3+ 
b7X12+b8X22+ b9X32  
Where b0 is the intercept representing the arithmetic mean 
of all quantitative outcomes of 17 runs; b1–b9 are the 
coefficients computed from the observed experimental 
response values of R; X1, X2 and X3 are the coded values of 
the independent variables; X1X2, X1X3, X2X3 are interaction 
terms and (X1)2, (X2)2, (X3)2 are quadratic terms. 
The magnitude of the coefficients represents the relative 
importance of each factor. 
Construction of contour plot 
Contour plots were drawn by using design expert version 
8.0.1.7. Four contour plot were drawn, the first contour plot 
of disintegration time was plotted against amount of Kyron 
T-314 and CRP, second contour plot of Q20 was plotted 
against amount of Kyron T-314 and CRP, third contour plot 
of wetting time was plotted against amount of Kyron T-314 
and CRP and forth contour plot of friability was plotted 
against amount of Kyron T-314 and CRP. 
Pre-compression parameters. 
The powder properties were evaluated with respect to angle 
of repose, bulk density, tapped density, hausner ratio and 
compressibility. All procedures were performed in triplicate.  
Angle of repose (θ): The angle of repose was determined by 
fixed funnel method where the height of the funnel was kept 
constant and adjusted in such a way that the apex of heap of 
the powder touched the funnel. The powder blend was 
allowed to flow and diameter of cone was measured12. 
Bulk and Tapped Density:  For Bulk density 10gms of 
powder blend for each formula was taken in measuring 
cylinder (50ml) and volume of the powder was measured 
after mild shaking. In case of tapped density the measuring 
cylinder was tapped on hard surface at height of 2.5 cm2 
until no change in volume was observed. The BD and TBD 
were calculated by taking mass to volume ratio13. 
ρo = M /Vb 
Where, ρo is bulk density, 
            M is mass of the blend and 
            Vb is Volume of blend 
Compressibility and Hausner’s ratio: The compressibility 
was determined by applying Carr’s Compressibility index 
that uses values of BD and TBD. The flowability of powder 
blend was determined by Hausner ratio as stated in USP14  
Compressibility was calculated using the following equation: 
% Compressibility= ρt- ρo / ρt *100 
 Where, 
ρt is the tapped density, 
ρo is the bulk density 
Post compression parameters 
Weight Variation Test 
To study weight variation was performed according to 
United state Pharmacopoeia (USP). 20 tablets of each 
formulation batch were taken and weighed on electronic 
balance. 20 tablets were randomly selected from each batch 
and weighed individually to check for weight variation.  
Thickness 
Five tablets were taken and thickness was measured using 
varnier calipers by placing tablet between two arms and 
note down the reading15  
Hardness 
The  hardness  of five tablets  of  each  batch  was  measured  
by  Monsanto  hardness  tester. 5 tablets were randomly 
selected and subjected for hardness test.  The hardness was 
measured in unit of kg/cm2. 15   
Friability 
Friability of the tablet was checked by Roche friabilator. Ten 
tablets were randomly selected from each batch and 
weighed. Pre-weighed tablets were placed in a friabilator, 
which was then operated for 4 min at 25 rpm. Tablets were 
dedusted and reweighed; the loss in the weight of the tablets 
was recorded and calculated for percentage change in weigh 
by following equation 15  
% Friability = [(W0- W1) / W0] 100 
Where, W0 is initial weight of tablets, W1 final weight of 
tablets 
Drug Content uniformity 
5 tablets were randomly selected, crush in mortar pestle and 
dissolved in 50 ml of 0.1 N HCl in 50 ml volumetric flak. The 
solution was stirred for 30 min and filtered. 1 ml of the 
filtrate was further diluted to 100 ml with 0.1 N HCl. 
Absorbance of this solution was measured at 274 nm. 
Content of LRD was calculated using regression line 
equation. 
Wetting Time 
A piece of filter paper was placed in a petridish with 10 cm 
diameter. 10 ml of water (containing water soluble dye 
Eosin) was added to the petridish. A tablet was carefully 
placed on the surface of the tissue paper. The time required 
to wet upper surface was measured as wetting time 16  
In-Vitro Disintegration time 
The assessment of the in vitro disintegration profile of 
orodispersible tablet is very important parameter in 
development of such formulations. The test was carried out 
on 6 tablets using tablet disintegration tester (Veego 
Machinery, India) in distilled water at 37°C ± 2° C was used 
as a disintegration media and time was noted for complete 
disintegration of the tablet with no palable mass remaining 
in the apparatus.  
In-vitro Dissolution study 
The release rate Loratadine from Orodispersible tablets was 
determined using United State Pharmacopoeia (USP) 
dissolution testing Type II apparatus. The dissolution test 
was performed using 900 ml of phosphate buffer pH 6.8, at 
37 ±0.5°C and 50 rpm. A sample (10 ml) of the solution was 
withdrawn from the dissolution apparatus at 2, 4, 6, 10, 15, 
20, 25 and 30 minutes. The samples were replaced with 
fresh dissolution medium of same quantity. The aliquots 
withdrawn were analyzed for drug content by taking 
absorbance at 274 nm using a UV spectrophotometer. % 
drug release was calculated and plotted against time. The 
experiment was performed in triplicate. 
Statistical Analysis 
Check point batch 
To confirm the validity of contour plot and equation 
generated by multiple regression analysis, check point 
batches were prepared in duplicate. The values of all 
possible combinations of three independent variables X1, X2 
and X3 were selected randomly. The results of the check 
point batches were compared with the response values of 
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R1, R2, R3 and R4 obtained from the equation generated. 
The amount of Kyron T-314, CRP and Pearlitol SD 200 
selected from contour plot and check point batches were 
prepared. 
24 factorial design. 
The magnitude of the coefficients represents the relative 
importance of each factor. 
The best equation may be selected from Half-Normal plot. 
The multiple regression coefficients R2 are a measure of it. If 
values of R2 = 1 or 0.91-0.99, it indicates good fit. R2 is sum 
of square due to regression/ sum of square without 
regression. 
The general form of the MLRA model is represented as the 
following equation: 
R = b0 + b1X1 + b2X2+ b3X3 + b4X1X2+ b5X1X3+ b6X2X3+ 
b7X12+b8X22+ b9X32  
Where b0 is the intercept representing the arithmetic mean 
of all quantitative outcomes of 17 runs; b1–b9 are the 
coefficients computed from the observed experimental 
response values of R; X1, X2 and X3 are the coded values of 
the independent variables; X1X2, X1X3, X2X3 are interaction 
terms and (X1)2, (X2)2, (X3)2 are quadratic terms. 
The magnitude of the coefficients represents the relative 
importance of each factor. 
Method also involves derivatization of regression fits using 
all possible combinations of independent variables. The best 
equation may be selected based on the fit and number of 
variables needed for it. The multiple regression coefficients 
R2 are a measure of it. If values of R2 = 1 or 0.91-0.99, it 
indicates good fit. R2 is sum of square due to regression/ 
sum of square without regression. 
Statistical analysis of the data and validation of model: 
Statistically validity of the model was established on the 
basis of ANOVA provision provided in the Design Expert 
software 8.0.1.7. Using 5% significance level, the model was 
considered significant, if the p value was less than 0.05. For 
Orodispersible formulation designed to minimum 
disintegration and wetting time and maximum % Drug 
release. So Orodispersible tablet was optimized with R1, R2 
and R3. Comparative study was carried for comparison 
between marketed product and prepared optimized tablet. 
Comparative study performed on various evaluation 
parameters like hardness, wetting time, disintegration time, 
drug content and In-vitro dissolution study. 
RESULT AND DISCUSSION 
To enhance the dissolution of drug from Orodispersible 
tablets Loratadine and β- cyclodextrin prepared by kneading 
method as described in our previous work11. The solubility 
was reported to be increased by 430 fold from 0.004 mg/ml. 
The solid dispersion of the β- cyclodextrin Loratadine 
complex in the molecular ratio of 1:3 was used.  The 
screening for various super disintegrating agents was 
carried out in which crosspovidone, sodium starch glycolate, 
kyron T314, and cross carmellose sodium etc was used.  The 
results from preliminary studies showed that formulations 
prepared with Crosspovidone and Kyron T314 as 
disintegrating agent has good correlation between the 
disintegrating time and wetting time. Hence, these two 
superdisintegrants were selected for further studies and 
employed in combination. The 24 factorial was designed 
accordingly.   
A two-level, four factor 24 full factorial design was utilized 
for screening of independent variable from four variables. 
The response variables measured were disintegrating time 
and wetting time. The summary of set parameters is given in 
Table 2. In 24 factorial design, four factors, the amount of 
super disintegrants, pore forming agent and hardness were 
evaluated. It was observed that formulations containing 
lower concentrations of super disintegrating agents showed 
disintegration time more than a minute compared to other 
formulations. Al though, it was found that no significant 
effect of hardness was observed on disintegration time. The 
least time taken for disintegration was by formulations F11, 
F13 and F15 where the amount of super disintegrants 
amount was higher. The entire primary batched in factorial 
design showed tablet friability under 1 %.  
The quicker disintegration time may be attributed to faster 
water uptake by the tablet. Kyron T-314 and CRP act by 
porosity and capillary action (Wicking). In this liquid is 
drawn up or “wicked” in through capillary action and 
rupture the inter-particulate bonds causing the tablet to 
break apart. Moreover, compared with other super 
disintegrants Kyron T-314 and CRP showed better 
compressibility, high capillary activity pronounced 
hydration capacity, and little tendency to form gels. The 
tablets containing SSG took more time for disintegration 
compared to other super disintegrating agents used.  This 
might be attributed to its slow swelling property of SSG. Pre-
compression parameters for all different combinations were 
found to be acceptable where bulk density, tapped density 
and compressibility found to be in between 0.454 to 0.531 
g/ml, 0.329 to .0371 g/ml and 9.09 % to 18.4% respectively. 
The powder blend was found to have a good flow property 
which was also confirmed from the results of angle of repose 
and Hausner’s ratio. The Angle of repose remained below 
30° for all preparation and Haursner’s ratio was obtained in 
the range of 1.1 to 1.3 indicative of free flow with no 
cohesive forces present. 
With the help of design expert software generated equations 
to quantify the effect of the formulation variables on the 
disintegrating time, wetting time. 
The equation representing the quantitative effect of 
independent variables on; 
Disintegration time (E1)= 27.63-57.87  X1 -25.88  X2 -8.31  X3 
-6.87  X4 -46.38  X1  X2 +0.94  X1  X3 -21.87  X1  X4 +0.94  X2  X3 
-9.38   X2 X4 -19.38  X1  X2  X4 
Wetting time (E2)= 28.75 -6.50  X1 -35.75  X2 +28.75  X3 -
8.75  X4 -2.00  X1  X2+44.25  X2  X3 -13.75  X2  X4 +16.25  X3  X4 
+18.75  X2  X3  X4 
Considering p-value (level of significance) less than 0.05, it 
was found that disintegration time (E1) was influenced 
significantly by X1, X2, X3 and E2 was influence significantly 
by X1, X2, X3. On other hand, X4 and their interaction were not 
able to give any significant effect on response variables. 
It is evident from the equations that factor X1 (Kyron T-314), 
X2 (CRP), X3 (Pearlitol SD200) and their interactions term 
contribute negatively to E1 and E2 whereas X4 (Hardness) 
and their interactions have not significant effect on E1 and 
E2. That is suggestive of decrease in disintegration time and 
wetting time. Therefore, further optimization study for X1, X2 
and X3 were carried out using Box-Behnken design. 
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Table 1: Composition of Loratadine ODT tablet and levels used in 24 Factorial design 
Ingredients Fixed level Factors 
Levels 
Low(-1) High(+1) 
LRD: β-CD complex 98 X1: Kyron T-314 2 % 6 % 
Kyron T-314 -- X2:CRP 5 % 10 % 
CRP -- X3:Pearlitol SD 200 15 % 25 % 
Pearlitol SD 200 -- X4: Hardness 3 kg/cm2 4 kg/cm2 
MCC  q.s  
Aspartame 4 
Talc 2 
Mg. Stearate 1 
 
Table 2: 24 Factorial design matrix and response 
Batch code X1 X2 X3 X4 
R1 
(Disintegration time) (sec) 
± SD 
R2 (Wetting time) 
(sec) ± SD 
F1 -1 -1 -1 1 64 ± 2.0 68 ± 3.08 
F2 +1 +1 -1 -1 47 ± 3.2 54 ± 3.21 
F3 +1 -1 +1 +1 33 ± 1.5 39 ± 3.1 
F4 +1 -1 -1 -1 51 ± 1.5 57 ± 0.5 
F5 -1 +1 -1 -1 57 ± 2.2 62 ± 2.5 
F6 -1 -1 1 +1 44 ± 1.5 48 ± 2.0 
F7 -1 +1 -1 +1 58 ± 1.3 64 ± 2.5 
F8 -1 +1 +1 +1 44 ± 2.0 48 ± 1.1  
F9 +1 -1 -1 +1 51 ± 2.3 59 ± 2.0 
F10 -1 -1 -1 -1 62 ± 1.6 67 ± 2.5 
F11 +1 +1 -1 1 24 ± 1.9 29 ± 2.3 
F12 +1 -1 +1 -1 33 ± 1.7 39 ± 2.7 
F13 +1 +1 +1 1 25 ± 1.8 29 ± 1.6 
F14 -1 +1 +1 -1 35 ± 1.6 39 ± 2.9 
F15 +1 +1 +1 -1 26 ± 1.5  33 ± 2.5 
F16 -1 -1 +1 -1 44 ± 2.01 47 ±1.52 
X1 code for amount of Superdisintegrant (Kyron T-314), X2 code for amount of Superdisintegrant (CRP), X3 code for amount of 
pore-forming agent (Pearlitol SD 200), X4 code for Hardness (kg/cm2) 
 
Statistical analysis of BoxBehnken Design 
A three-factor, three-level Box-Behnken design was utilized 
for optimization of the Loratadine Orodispersible tablet. The 
dependent variables measured were disintegrating time, 
wetting time, Cumulative % drug release at 20 min (Q20). 
The composition and responses of the Box-Behnken design 
are shown in Table 3. The pre compression parameters 
evaluated are shown in Table 4. Among the different batches 
prepared according to Box behnken design, Disintegration 
time, wetting time, drug release (Q 20), friability & hardness 
was found in the range of   23± 2.5 to 59±2.6, 27±0.5 to 66.3 
± 3.0, 86.1±0.6 to 96.7±0.5, 0.3 to 0.7 %, and 3.4 to 4.2 
Kg/cm2 respectively. FB1, FB9 and FB15 showed most 
suitable parameters in order of FB15>FB1>FB9 with FB15 
showing least disintegration time of 23 sec and wetting time 
of 27 sec. The percentage friability was in between 0.3 to .7 
% that is very much under the limits specified in 
pharmacopeia. With hardness of nearly 4 and friability less 
than 0.7 percent all formulation showed good mechanical 
strength of tablets. It was also noted that higher amount of 
Pearlitol contributed in achieving better friability. 
The disintegration time for all formulation from FB1 to FB17 
was found to be less than a minute except formulation 
batches FB2, FB7 and FB13. Surface plot of the effect of CRP 
and Kyron T314 on disintegration time is shown in Figure 1 
(a,b). The disintegration time of tablet was found to decrease 
when amount of CRP and KT were increased. S chaturvedi et 
al reported the faster disintegrating effect of KT at higher 
level when compared to Crosscarmellose for the direct 
compressible fast dissolving tablet containing losartan 
potassium17. With the help of MLRA, Design expert software 
8.0.7.1 generated equations to quantify the effect of the 
formulation variables on the disintegrating time, wetting 
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Table 3: Box-Behnken design matrix and response 
Box-Behnken design     
Batch 
code 









FB1 -1 4.00 0 10.00 0 25.00 28± 1.1 33± 0.5 95.1±0.4 0.45± 0.04 
FB2 +1 2.00 -1 5.00 0 20.00 70± 2.6 63± 1.5 88.7±0.6 0.52± 0.06 
FB3 0 2.00 -1 7.50 +1 25.00 38± 1.5 43± 2.5 93.4±0.6 0.35± 0.10 
FB4 0 2.00 0 10.00 0 20.00 45± 2.4 50± 2.9 93.6±0.4 0.56± 0.01 
FB5 -1 6.00 +1 7.50 0 15.00 49± 2.6 52± 2.1 92.3±1.3 0.61± 0.07 
FB6 0 4.00 0 7.50 0 20.00 45± 1.1 50± 3.4 93.6±0.7 0.56± 0.02 
FB7 -1 4.00 0 5.00 +1 15.00 68± 1.3 66± 3.4 86.1±0.6 0.62± 0.04 
FB8 0 4.00 +1 7.50 +1 20.00 45± 1.5 50± 2.6 92.5±0.3 0.56± 0.04 
FB9 0 6.00 0 10.00 0 20.00 45± 2.4 50± 2.9 93.6±0.4 0.56± 0.01 
FB10 0 4.00 0 7.50 0 20.00 45± 2.4 50± 2.9 93.6±0.4 0.56± 0.01 
FB11 +1 4.00 0 10.00 -1 15.00 50± 2.8 53± 2.5 95.3±0.5 0.70± 0.03 
FB12 0 4.00 0 7.50 0 20.00 45± 2.4 50± 2.9 93.6±0.4 0.56± 0.01 
FB13 0 2.00 -1 7.50 -1 15.00 66± 2.6 63± 3.1 92.4±0.6 0.59± 0.02 
FB14 +1 4.00 0 7.50 +1 20.00 45± 1.5 50± 2.5 93.6±0.3 0.56± 0.10 
FB15 +1 6.00 +1 7.50 0 25.00 23±2.5 27± 0.5 96.7±0.4 0.34± 0.04 
FB16 0 4.00 +1 5.00 -1 25.00 38±1.5 46± 1.1 89.8±0.6 0.31± 0.03 
FB17 -1 6.00 0 5.00 -1 20.00 46±1.15 55 ± 3.0 87.8±0.4 0.49± 0.02 
X1 code for amount of Superdisintegrant (Kyron T-314), X2 code for amount of Superdisintegrant (CRP), X3 code for amount of 
pore-forming agent (Pearlitol SD 200)  
Table 4: Micromeritic properties of powder blend of LRD Orodispersible tablets 









FB1 24.84° 0.45 0.51 9.09 1.1 
FB2 28.52° 0.41 0.52 20.83 1.26 
FB3 22.83° 0.41 0.52 24.30 1.31 
FB4 25.60° 0.45 0.55 18.18 1.22 
FB5 29.16° 0.37 0.47 22.22 1.28 
FB6 26.11° 0.38 0.45 15.38 1.18 
FB7 32.00° 0.37 0.47 22.22 1.28 
FB8 26.11° 0.38 0.45 15.38 1.18 
FB9 23.68° 0.40 0.45 12.08 1.13 
FB10 26.11° 0.38 0.45 15.38 1.18 
FB11 25.64° 0.35 0.43 17.85 1.21 
FB12 26.11° 0.38 0.45 15.38 1.18 
FB13 30.34° 0.43 0.52 24.12 1.31 
FB14 26.11° 0.38 0.45 15.38 1.18 
FB15 24.87° 0.41 0.47 12.50 1.14 
FB16 23.19° 0.43 0.52 13.04 1.15 




Surface plot showing relationship between 
disintegrating time (R1) and amount of X1 
(Kyron T-314) and X2 (CRP) 
Surface plot showing relationship between 
wetting time (R23) and amount of X1 (Kyron T-
314) and X2 (CRP) 
Figure 1(A): Surface Plot showing Different relationship of amount of Super disintegrants to 
response 
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Surface plot showing relationship between Q20 
(R3) and amount of X1 (Kyron T-314) and X2 
(CRP) 
Surface plot showing relationship between 
friability (R4) and amount of X1 (Kyron T-314) 
and X2 (CRP 
Figure 1(B): Surface Plot showing Different relationship of amount of Super disintegrants to response 
The equation representing the quantitative effect of 
independent variables on; 
Disintegration Time (R1) = 45.00 - 5.50 X1 - 4.12  X2 - 11.13  
X3 - 0.25  X1  X2 - 1.25  X1  X3 - 0.50  X2  X3 + 0.25  X12 + 1.50  
X22 - 3.00  X32  
Wetting Time (R2) = 50.00 - 5.75  X1 - 6.88  X2 - 10.63  X3 - 
0.75  X1  X2 - 1.25  X1  X3 + 0.000  X2  X3 - 0.75  X12 + 2.50  X22 - 
3.00  X32 
Q20 (R3) = + 93.60 - 0.087  X1 + 4.03  X2 + 0.69  X3 + 0.22  X1  
X2 + 0.10  X1  X3 - 1.08  X2  X3 - 0.37  X12 - 1.15  X22  - 0.27  X32 
Friability (R4)= 0.56 + 2.500E-003  X1  + 0.065  X2 - 0.14  X3 
+ 0.017  X1  X2 - 7.500E-003  X1  X3 + 0.018  X2  X3 - 0.014  X12 
+ 0.031  X22 - 0.074  X32 
The polynomial equations comprise the coefficients for 
intercept, first-order main effects, interaction terms and 
higher order effects. Positive sign against the individual term 
indicated synergistic effect while negative sign indicated 
antagonistic effect of the factors. 
The values of the coefficients X1, X2 & X3 relate to the main 
effects of these variables on the corresponding response. 
It was evident from the equations that factor X1 (Kyron T-
314) and their interactions term contribute negatively to R1, 
R2 and R3 whereas positively to R4. X2 (Crospovidone) and 
their interaction terms contribute negatively to R1, R2 
whereas positively to R3 and R4. X3 (Pearlitol SD200) and 
their interaction terms contributes negatively R1, R2 and R3 
and positively to R4. 
Considering p-value (level of significance) less than 0.05, it 
was found that R1 was influenced significantly by X1, X2, X3, 
X22 and X32, R2 was influence significantly by X1, X2, X3, X22 
and X32, R3 by X2, X3, X2X3, X22, X32. Remaining terms had 
non- significant (p> 0.05) contribution to the response 
variables. 
The three factors Kyron T-314, CRP and Pearlitol SD200 
were selected as independent variables and Disintegration 
time (DT), Wetting (WT) and % drug release at 20 min (Q20) 
were set as response variable in Box-Behnken design. Total 
of 17 batches [FB1-FB17] were prepared and evaluation was 
carried out. From All batches FB15 showed good result i.e 
DT of 23 sec, WT of 27 sec and Q20 of 96.7 % and regarded 
as optimized formulation.  
Box-Behnken design gave regression equation for response 
for selected variables within selected range selected for 
those variables. Validity of these equations is confirmed 
within those selected range by taking check point batches at 
particular value of those selected variables. 
 
  
Contour plot for Disintegration time with check 
point batch value 
Contour plot for wetting time (R2) with check 
point batch value 
  
Contour plot for Q20 (R3) with check point 
batch value 
Contour plot for Friability (R4) with check point 
batch value 
Figure 2:  Contour plot for Disintegration time with check point batch value 
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The % relative error obtained from checkpoint batch was in 
the range of 3.426-1.349. It can be seen that in all cases there 
was a reasonable agreement of predicted values and 
experimental values, since low values of the relative error 
were found. This confirmed the role of a derived reduced 
polynomial equation, proved the validity of the model and 
ascertained the effects of Kyron T-314, CRP and Pearlitol 
SD200 on disintegrating time, cumulative % drug release at 
20 min, wetting time and friability. The contour plots are 
shown in Figure 2. 
Surface plot for each response 
Surface plots were obtained for the measured response 
based on the model using Design-Expert® software. A 
response surface graph shows the response as a function of 
factor level. 
Three dimensional response surface graphs for R1 and R2 
were drawn for two factors only keeping the third factor 
constant. Significant influences of each independent variable 
on depend-ent variables are observed from all response 
surface graphs. The relationship between the independent 
variables and the response can be further explained by using 
these surface plots.  
In-vitro Dissolution study  
The drug release was expected to be faster as the drug β-
cyclodextrin complex was used in the preparation of 
Orodispersible tablet. All the formulation showed cumulativ 
drug release of greater than 85% in 20 mins. Formulation 
batches FB1, FB11 and FB15 showed more than 95% drug 
release in 20 mins. The formulation batches FB16, FB 17 and 
FB2 showed lesser dissolution rate below 90%. It was 
observed that amount of disintegrating agent influences the 
dissolution rate and disintegrating time. Higher 
concentration of disintegrating agent resulted lower 
disintegration and wetting time. The graphical 
representation of in vitro drug release in shown in Figure 3. 
 
 
Figure 3: In-vitro drug release of batches FB1-FB17 
 
Optimized Formulation of Loratadine Orodispersible 
tablet:- 
The selection of best formulation depends on minimum 
disintegration & wetting time, maximum % drug release at 
20 min (Q20). So, above criteria for optimized formulation 
was meeting with batch FB15 which have disintegration 
time of 23 sec, wetting time of 27 sec, friability of 0.34 and 
drug release of 94.7% at 20 min. So the batch FB15 was 
found to be the best fit formulation among all other batches. 
The optimized Orodispersible tablet (FB15) when compared 
with Lorfast melt tab (cadila pharma) showed no difference 
in the hardness and drug content, comparative data are 
shown in Table 6. However, FB15 showed reduced 
disintegration time and wetting time. FB15 batch found to 
release the drug much faster than marketed product 
(LORFAST MELTAB). Hence it can be concluded that the 
formulated LRD Orodispersible tablets were superior to 
marketed LORFAST MELTAB to achieve fast therapeutic 
response in the form of orodispersible tablet. 
 
Table 5: Experimental values and predicted value of the check point batches 
Response  Batch Predicted value Experimental value % Relative error 
Disintegration time C1 49.66 50.33 -1.349 
C2 39.69 38.33 3.426 
Wetting time C1 42.47 43 -1.247 
C2 54.96 54.33 1.146 
Q20 C1 92.63 91.3 1.435 
C2 96.09 95.1 1.030 
Friability C1 0.542 0.543 -0.184 
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Table 6: Comparative evaluation study with LORFAST MELTAB (n=3) 
Evaluation Marketed tablet (Lorfast melt tab) Batch FB15 
Hardness (kg/cm2 ) 3.0 ± 0.1 3.4 ± 0.1 
Friability (%) 0.64 ± 0.07 0.34 ± 0.03 
Wetting time (second) 36 ± 3.9 27 ± 1.8 
Disintegration time (second) 29 ± 3.3 23 ± 1.6 
Drug content (%) 99.1 ± 3.4 98.6 ± 2.8 
Q20 (%) 62.9 ± 2.0 94.7 ± 2.4 
 
CONCLUSION:  
Orodispersible tablet prepared using combination of two 
superdisintegrants, Kyron 314 and CRP, showed satisfactory 
tablet properties. The factorial design and box Behnken 
design revealed that superdisintegrant concentration has 
significant influence on wetting time, disintegration time, 
friability and drug release from Orodispersible tablet. The 
superdisintegrant combination and use of Mannitol resulted 
in optimal tablet properties. Formulations FB15 was chosen 
as optimal formulations that fulfilled specific requirement of 
ODT. Being advantageous over wet granulation, the 
Orodispersible tablets of Loratidine were successfully 
prepared by direct compression method using Loratidine- β-
CD complex and super disintegrating agents. The drug β-CD 
complex along with faster dispersion could increase 
bioavailability of drug.  
REFERENCES: 
1. Habib W, Khankari R, and Hontz J, Fast dissolve drug delivery 
systems. Critical Review Therapeutic Drug carrier system, 
2000; 17(1): 61-72. 
2. Ghosh TK, Chatterjee DJ and Pfister, WR, Quick dissolving oral 
dosage forms: scientific and regulatory considerations from a 
clinical pharmacology and biopharmaceutical perspective. 
CRC press, New York. 2005. P. 337-356.  
3. Kaushik D, Dureja H, Saini TR, Orally disintegrating tablets: An 
overview of melt-in mouth tablet technologies and 
techniques. Tablets and Capsules, 2004; 2(4): 30-36. 
4. Kamboj M, Goyal S, Rakha P, Arora G, Dureja H And Nagpal M, 
Formulation and evaluation of metformin oro-dispersible 
tablets, Acta Poloniae Pharmaceutica Drug Research, 2011; 
68( 5): 717-723. 
5. Gissinger D and Stamm A, Comparative Evaluation of the 
Properties of. Some Tablet Disintegrants. Drug Development 
and Industrial Pharmacy, 1980; 6: 511-36.  
6. Bi Y, Preparation and evaluation of compressed tablet rapidly 
disintegrating in the oral cavity, Chemical and Pharmaceutical 
Bulletin, 1996; 44(11):2121-2127. 
7. BASF Technical Literature, Kollidone Polyvinylpyrrolidone for 
pharmaceutical industry, BASF Aktiengesellschaft, Fine 
Chemicals, D- 67056, Ludwigshafen; March 1998 (4th 
edition)., 
8. European pharmacopoeia, 6th edition,vol.1, 2008. P. 750. 
9. Kay GG, Harris AG, Loratadine: a non-sedating antihistamine. 
Review of its effects on cognition, psychomotor performance, 
mood and sedation. Clinical Experimental Allergy, 1999; 
3:147-150.  
10. Kreutner W, Chapman RW, Gulbenkian A, Siegel MI,. 
Antiallergic activity of loratadine, a non‐sedating 
antihistamine, Allergy,1987; 42(1): 57-63.  
11. Kundawala AJ, Patel P, Solubility Enhancement of Loratadine 
by Solid Dispersion Techniques. International Journal of 
Chemtech and Research, 2017; 10(7): 207-217. 
12. Cooper J, Gunn C, Powder flow and compaction. In: Carter, S.J. 
(Ed.), Tutorial Pharmacy. CBS Publishers and Distributors, 
New Delhi, India, 1986. P. 211–233. 
13. Shah D, Shah Y, Rampradhan M, Development and evaluation 
of controlled release diltiazem hydrochloride microparticles 
using cross-linked poly (vinyl alcohol). Drug Development and 
Industrial Pharmacy, 1997; 23: 567–574. 
14. United States Pharmacopeia 24/NF19, 2000. The Official 
Compendia of Standards. Asian Rockville, M.D. (Ed.), United 
States Pharmacopoeia Convention Inc, pp. 1913–1914. 
15. Banker GS, Anderson NRI, In:Lachman,L., Lieberman,H.A., 
Kanig, J.L. (Eds.), The Theory and Practice of Industrial 
Pharmacy, third ed. Varghese Publishing House, Mumbai, 
1987. P. 293–299. 
16. Tejvir K, Bhawandeep G, Sandeep K, Gupta GD, Mouth 
dissolving tablets: a novel app to drug delivery. International 
journal of current pharmaceutical research, 2011; 3 (1): 1–7. 
17. Chaturvedi S, Agrawal V, Singh S, Impact of superdisintegrants 
on the release of oro-dispersible tablets of losartan 
potassium: A comparative analysis.  Der Pharmacia Lettre, 
2012; 4 (6):1768-1776. 
 
